Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Exclusion Criteria

• •1. History or evidence of decompensated liver disease,
• •2. Hepatitis and fibrosis more likely related to etiologies other than non-alcoholic steatohepatitis (NASH).
• •3. Participant has urine ethyl glucuronide (EtG) \> 500 ng/mL at Screening.
• •4. History or positive screen for human immunodeficiency virus (HIV) infection or congenital or human immunodeficiency virus (HIV)-unrelated acquired immunodeficiencies (eg, common variable immunodeficiency \[CVID\]).
• •5. History of hepatitis B and/or hepatitis C.
• •6. History of malignancy within the last 5 years (exceptions: excised and cured basal/squamous cell skin carcinomas and cervical carcinoma in situ).
• •7. Pregnancy or lactation.